Consideration of use of phenothiazines in particular trifluorperazine for epidermal growth factor receptor associated cancers

Area of Science:

• Oncology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) signaling is crucial for numerous cancers.
• Phenothiazines, like trifluorperazine (Stelazine), are FDA-approved and commonly used for schizophrenia.
• Previous research indicated phenothiazines downregulate EGFR.

Purpose of the Study:

• To explore the potential of phenothiazines as a novel therapeutic strategy for EGFR-associated cancers.
• To investigate the role of trifluorperazine in targeting EGFR signaling in various malignancies.

Main Methods:

• Literature review of existing studies on phenothiazines and EGFR.
• Analysis of cancer dependency on EGFR signaling pathways.
• Hypothesizing therapeutic applications based on EGFR downregulation.

Main Results:

• Phenothiazines, particularly trifluorperazine, have been shown to downregulate EGFR.
• EGFR signaling is a key driver in cancers such as colon, breast, pancreatic, and glioblastoma.
• This downregulation mechanism presents a potential anti-cancer effect.

Conclusions:

• Phenothiazines, including trifluorperazine, show promise for treating EGFR-dependent cancers.
• Consideration of trifluorperazine for EGFR-associated malignancies is warranted.
• Further research into phenothiazine-based cancer therapies is suggested.